Could a cream help control Early-Stage skin lymphoma?

NCT ID NCT06698822

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This phase 2 trial tests a cream containing tofacitinib, a drug that calms the immune system, for people with early-stage cutaneous T-cell lymphoma (CTCL). The study will include 20 adults with stage IA, IB, or IIA disease. Researchers want to see if the cream is safe and can help control the skin lymphoma without needing stronger treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tofacitinib 2% cream
What this could lead to: If it works, this could offer a new topical treatment option for early-stage cutaneous T-cell lymphoma, potentially controlling the disease with fewer side effects than systemic therapies.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The cream may not be effective or could cause skin irritation or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary cutaneous T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS T-CELL LYMPHOMA

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.